• Tandem Diabetes Care held its annual shareholder meeting on May 20, 2026, with shareholders backing amendments to the company’s charter.
• The charter changes were adopted to allow directors to be removed with or without cause; the amendment was approved, then filed on May 21, 2026.
• Shareholders also authorized officer exculpation to the maximum extent permitted by law, along with other charter updates; the amendment was approved, then included in the May 21, 2026 charter filing.
• An amended 2023 long-term incentive plan was approved to increase the share pool by 3,260,000 shares; the vote authorized the plan change but does not confirm any shares have been issued.
• Ernst & Young was ratified as independent auditor for the fiscal year ending Dec. 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tandem Diabetes Care Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001438133-26-000070), on May 21, 2026, and is solely responsible for the information contained therein.